
Need professional-grade analysis? Visit stockanalysis.com
$761.95B
21.83
27,707
N/A
Price Chart
Risk-Adjusted Performance
Aurobindo Pharma Limited (AUROPHARMA) Price Performance
Aurobindo Pharma Limited (AUROPHARMA) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR1281.60, down 0.76% from the previous close.
Over the past year, AUROPHARMA has traded between a low of INR1022.20 and a high of INR1311.90. The stock has gained 11.3% over this period. It is currently 25.4% above its 52-week low.
Aurobindo Pharma Limited has a market capitalization of $761.95B, with a price-to-earnings ratio of 21.83.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Company Info
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
- Country
- India
Financial Metrics
- Revenue (TTM)
- $331.82B
- EBITDA
- $66.86B
- Profit Margin
- 10.51%
- EPS (TTM)
- 60.09
- Book Value
- 603.39
Technical Indicators
- 52 Week High
- ₹1,319.80
- 52 Week Low
- ₹1,006.22
- 50 Day MA
- ₹1,188.83
- 200 Day MA
- ₹1,144.97
- Beta
- 0.06
Valuation
- Trailing P/E
- 21.83
- Forward P/E
- 8.21
- Price/Sales
- 2.30
- Price/Book
- 2.16
- Enterprise Value
- $744.60B